Showing 3321-3330 of 6665 results for "".
- IL-17 Inhibitors Not Linked to MACE: Analysishttps://practicaldermatology.com/news/il-17-inhibitors-not-linked-to-maces/2483300/Results from a large French case–time–control study revealed no association between the administration of interleukin (IL)-17 receptor A inhibitors and major adverse cardiovascular events (MACE). Researchers used data from mo
- Biologics Most Likely to Be Continued After MACE: Studyhttps://practicaldermatology.com/news/biologics-most-likely-to-be-continued-after-mace-study/2483287/Biologic therapies were linked with greater treatment persistence than non-biologic systemic agents or phototherapy among patients with psoriasis who experience major adverse cardiovascular events (MACE), according to findings from a retrospective study of Korean n
- Psoriasis Patients Show Significant Link to Metabolic Syndrome in Indian Studyhttps://practicaldermatology.com/news/psoriasis-patients-show-significant-link-to-metabolic-syndrome-in-indian-study/2483264/A hospital-based cross-sectional study from India has found that patients with chronic plaque psoriasis show a significant association with metabolic syndrome, highlighting the importance of routine metabolic screening in dermatology practice. Published in <
- Long-Term Data Support Safety of Upadacitinib in Women With AD Using OCPshttps://practicaldermatology.com/news/long-term-data-support-safety-of-upadacitinib-in-women-with-ad-using-ocps/2483285/Upadacitinib maintains a favorable benefit–risk profile in women with moderate-to-severe atopic dermatitis (AD), regardless of oral contraceptive pill (OCP) or hormone replacement therapy (HRT) use, according to long-term safety data presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) C
- Analysis Links NHR With Increased Risk of PsOhttps://practicaldermatology.com/news/analysis-links-nhr-with-increased-risk-of-pso/2483261/The neutrophil-to-high-density lipoprotein cholesterol ratio (NHR) is independently associated with an increased risk of psoriasis, raising the possibility of a novel biomarker for risk stratification, according to a large cross-sectional analysis of US adults published in Frontiers in Immuno
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- ASDSA Pushes for Stronger Sun Protection Through SUNucate Legislationhttps://practicaldermatology.com/news/asdsa-pushes-for-stronger-sun-protection-through-sunucate-legislation/2482983/The American Society for Dermatologic Surgery Association (ASDSA) has updated its SUNucate model legislation to expand its reach beyond sunscreen use in schools and school-sponsored events, according to a news release. The SUN
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations